JP2014523736A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523736A5 JP2014523736A5 JP2014513311A JP2014513311A JP2014523736A5 JP 2014523736 A5 JP2014523736 A5 JP 2014523736A5 JP 2014513311 A JP2014513311 A JP 2014513311A JP 2014513311 A JP2014513311 A JP 2014513311A JP 2014523736 A5 JP2014523736 A5 JP 2014523736A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- test substance
- double
- gene
- stranded molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 claims 24
- 101150005895 suv39h2 gene Proteins 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 230000014509 gene expression Effects 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 230000005764 inhibitory process Effects 0.000 claims 10
- 108091081021 Sense strand Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 230000000692 anti-sense effect Effects 0.000 claims 8
- 230000010261 cell growth Effects 0.000 claims 7
- 230000004071 biological effect Effects 0.000 claims 6
- 239000003153 chemical reaction reagent Substances 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 238000012216 screening Methods 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- 108700008625 Reporter Genes Proteins 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 claims 2
- 102100028988 Histone-lysine N-methyltransferase SUV39H2 Human genes 0.000 claims 2
- 101000696699 Homo sapiens Histone-lysine N-methyltransferase SUV39H2 Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 102000016397 Methyltransferase Human genes 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 108091027568 Single-stranded nucleotide Proteins 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161493235P | 2011-06-03 | 2011-06-03 | |
| US61/493,235 | 2011-06-03 | ||
| PCT/JP2012/003569 WO2012164936A1 (en) | 2011-06-03 | 2012-05-31 | Suv39h2 as a target gene for cancer therapy and diagnosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523736A JP2014523736A (ja) | 2014-09-18 |
| JP2014523736A5 true JP2014523736A5 (https=) | 2015-07-02 |
| JP6064231B2 JP6064231B2 (ja) | 2017-01-25 |
Family
ID=47258808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513311A Expired - Fee Related JP6064231B2 (ja) | 2011-06-03 | 2012-05-31 | がん治療および診断のための標的遺伝子としてのｓｕｖ３９ｈ２ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20140094387A1 (https=) |
| EP (1) | EP2714903B1 (https=) |
| JP (1) | JP6064231B2 (https=) |
| WO (1) | WO2012164936A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20125554L (fi) | 2012-05-25 | 2013-11-26 | Univ Bern | Menetelmä perinnölliseen nasaaliseen parakeratoosiin (HNPK) liittyvän genotyypin määrittämiseksi ja menetelmässä käyttökelpoisia nukleiinihappoja |
| EP3194581A4 (en) | 2014-09-15 | 2018-04-25 | Children's Medical Center Corporation | Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation |
| CN109072219B (zh) * | 2015-12-28 | 2024-02-27 | 北海道公立大学法人札幌医科大学 | 肿瘤抗原肽 |
| CN121202972B (zh) * | 2025-09-23 | 2026-04-03 | 北京大学 | 一种靶向suv39h1的短肽及其在治疗肿瘤中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020039776A1 (en) * | 2000-06-09 | 2002-04-04 | Thomas Jenuwein | Mammalian SUV39H2 proteins and isolated DNA molecules encoding them |
| JP4896344B2 (ja) * | 2000-06-09 | 2012-03-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | メチルトランスフェラーゼ依存性染色体安定性の調節因子のスクリーニング方法 |
| US6555329B2 (en) * | 2000-06-09 | 2003-04-29 | Boehringer Ingelheim International Gmbh | Method for identifying compounds altering higher-order chromatin-dependent chromosome stability |
| JP2003277288A (ja) * | 2001-12-27 | 2003-10-02 | Takeda Chem Ind Ltd | がんの予防・治療剤 |
| WO2005116204A1 (ja) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| JP5629894B2 (ja) * | 2004-12-07 | 2014-11-26 | 国立大学法人大阪大学 | 甲状腺乳頭癌を診断するための新規のマーカー |
| EP2311985A1 (en) * | 2005-07-27 | 2011-04-20 | Oncotherapy Science, Inc. | Sirna for treating esophageal cancer |
| WO2008073290A1 (en) * | 2006-12-08 | 2008-06-19 | The Board Of Trustees Of The University Of Arkansas | Tp53 gene expression and uses thereof |
| WO2009126537A1 (en) * | 2008-04-07 | 2009-10-15 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac and an hmt inhibitor |
| WO2009126970A1 (en) * | 2008-04-11 | 2009-10-15 | The Translational Genomics Research Institute | Method of assessing sensitivity to brostallicin |
| EP2145964A1 (en) * | 2008-07-17 | 2010-01-20 | Universität Zu Köln | A method for lung cancer early detection and prognosis |
-
2012
- 2012-05-31 JP JP2014513311A patent/JP6064231B2/ja not_active Expired - Fee Related
- 2012-05-31 EP EP12792440.5A patent/EP2714903B1/en not_active Not-in-force
- 2012-05-31 WO PCT/JP2012/003569 patent/WO2012164936A1/en not_active Ceased
- 2012-05-31 US US14/123,403 patent/US20140094387A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Long noncoding RNA RC3H2 facilitates cell proliferation and invasion by targeting MicroRNA-101-3p/EZH2 axis in OSCC | |
| JP2009502115A5 (https=) | ||
| JP2012135301A5 (https=) | ||
| Shi et al. | Potential involvement of miR-375 in the premalignant progression of oral squamous cell carcinoma mediated via transcription factor KLF5 | |
| JP2012501164A5 (https=) | ||
| JP2008532477A5 (https=) | ||
| Yu et al. | MiR-1 targets PIK3CA and inhibits tumorigenic properties of A549 cells | |
| Fox et al. | Targeting of TGFβ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma | |
| JP2010538610A5 (https=) | ||
| Duan et al. | Prognostic significance of miRNA‐1 (miR‐1) expression in patients with chordoma | |
| Bondy-Chorney et al. | RNA binding protein RALY promotes Protein Arginine Methyltransferase 1 alternatively spliced isoform v2 relative expression and metastatic potential in breast cancer cells | |
| JP2010535014A5 (https=) | ||
| Salameh et al. | HER3 and LINC00052 interplay promotes tumor growth in breast cancer | |
| CN108753969B (zh) | 长链非编码rna在肝细胞癌诊疗中的应用 | |
| JPWO2019208671A5 (https=) | ||
| JP2014523736A5 (https=) | ||
| Bersani et al. | Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity | |
| KR20110015013A (ko) | 결장직장암의 평가 방법 및 여기에 사용하기 위한 조성물 | |
| CN107586850B (zh) | 非编码基因在肝癌诊疗中的应用 | |
| KR102424454B1 (ko) | Tut4/7 발현 조절인자를 포함하는 암 예방 또는 치료용 약학적 조성물 | |
| CN105457041B (zh) | miR-26a在非小细胞肺癌中的应用 | |
| KR101625755B1 (ko) | ｍｉＲＮＡ 스폰지 및 이의 용도 | |
| RU2011111551A (ru) | C12orf48 как ген-мишень для лечения и диагностики рака | |
| JP2009505633A5 (https=) | ||
| JP2009159869A5 (https=) |